Seattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 Shares

Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $51.71, for a total transaction of $973,802.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Clay B. Siegall also recently made the following trade(s):

  • On Monday, December 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The stock was sold at an average price of $55.40, for a total transaction of $1,043,292.80.
  • On Friday, November 10th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The stock was sold at an average price of $58.00, for a total transaction of $1,092,256.00.

Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) opened at $50.95 on Wednesday. The stock has a market cap of $7,330.00, a price-to-earnings ratio of -58.56 and a beta of 2.37. Seattle Genetics, Inc. has a 12 month low of $45.31 and a 12 month high of $71.32.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.23. The company had revenue of $135.29 million for the quarter, compared to the consensus estimate of $112.76 million. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. Seattle Genetics’s revenue was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.23) earnings per share. analysts predict that Seattle Genetics, Inc. will post -0.93 earnings per share for the current fiscal year.

SGEN has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $46.00 price target on shares of Seattle Genetics and gave the stock a “hold” rating in a research report on Monday, October 2nd. SunTrust Banks reiterated a “hold” rating and issued a $45.00 price target on shares of Seattle Genetics in a research report on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $64.00 target price on shares of Seattle Genetics in a research report on Friday, October 6th. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Tuesday, October 10th. Finally, Oppenheimer initiated coverage on shares of Seattle Genetics in a research report on Tuesday, October 10th. They set a “hold” rating for the company. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $63.76.

A number of institutional investors have recently added to or reduced their stakes in SGEN. Schwab Charles Investment Management Inc. raised its stake in Seattle Genetics by 6.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 296,212 shares of the biotechnology company’s stock valued at $15,327,000 after purchasing an additional 17,130 shares in the last quarter. Prudential Financial Inc. raised its stake in Seattle Genetics by 6.8% during the second quarter. Prudential Financial Inc. now owns 6,291 shares of the biotechnology company’s stock valued at $325,000 after purchasing an additional 400 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Seattle Genetics during the second quarter valued at $343,000. Alliancebernstein L.P. raised its stake in Seattle Genetics by 1.1% during the second quarter. Alliancebernstein L.P. now owns 57,241 shares of the biotechnology company’s stock valued at $2,962,000 after purchasing an additional 603 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in Seattle Genetics by 55.2% during the second quarter. Teachers Advisors LLC now owns 554,091 shares of the biotechnology company’s stock valued at $28,669,000 after purchasing an additional 197,143 shares in the last quarter. 98.89% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Seattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 Shares” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.truebluetribune.com/2018/01/17/seattle-genetics-inc-sgen-insider-clay-b-siegall-sells-18832-shares.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply